Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes
Dateline City:
WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA
WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Samsung Bioepis Co., Ltd., announced today that they have expanded their
collaboration with an agreement to develop, manufacture and
commercialize MK-1293, an insulin glargine candidate for the treatment
of patients with type 1 and type 2 diabetes. Phase III clinical studies
in type 1 and type 2 diabetes will begin soon.
Languag...
Source: Merck.com - Corporate News - February 10, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Announces Fourth-Quarter and Full-Year 2013 Financial Results
Dateline City:
WHITEHOUSE STATION, N.J.
Fourth-Quarter 2013 Non-GAAP EPS Increased by 6 Percent Over Prior Year to $0.88, Excluding Certain Items; GAAP EPS Decreased by 13 Percent to $0.26. Full-Year 2013 Non-GAAP EPS of $3.49, Excluding Certain Items; GAAP EPS of $1.47.
Fourth-Quarter 2013 Worldwide Sales Were $11.3 Billion, a Decrease of 4 Percent Reflecting Unfavorable Impact of Patent Expiries and a 3 Percent Negative Impact from Foreign Exchange.
...
Source: Merck.com - Corporate News - February 5, 2014 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference
Dateline City:
WHITEHOUSE STATION, N.J.
Initiates rolling submission of U.S. Biologics License Application (BLA) for MK-3475, the company’s anti-PD-1 immunotherapy; expects to complete application in first half of 2014.
Prepares for 2014 regulatory actions for V503, vintafolide (EU), vorapaxar, NOXAFIL IV, vaniprevir (Japan) and AIT-Grass and AIT-Ragweed; anticipates filing odanacatib, suvorexant.
Evaluates the role of Merck’s Animal Health and Cons...
Source: Merck.com - Corporate News - January 13, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Kenneth C. Frazier, Merck's chairman and chief
executive officer, is scheduled to present at the 32nd Annual
J.P. Morgan Healthcare Conference in San Francisco on January 13 at 4:00
p.m. PST (7:00 p.m. EST). Investors, analysts, members of the media and
the general public are invited to listen to a live audio webcast of the
presentation at http://www.merck....
Source: Merck.com - Corporate News - January 10, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Receives FDA Approval for ISENTRESS® (raltegravir) for Pediatric Oral Suspension
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA)
recently approved ISENTRESS® for oral suspension, a new
pediatric formulation of Merck’s integrase inhibitor. With this
approval, ISENTRESS is now indicated in combination with other
antiretroviral (ARV) agents for the treatment of HIV-1 infection in
patients four weeks of age and older.
Language:
...
Source: Merck.com - Corporate News - January 8, 2014 Category: Pharmaceuticals Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck to Hold Fourth-Quarter 2013 Sales and Earnings Conference Call on February 5
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
will hold its fourth-quarter 2013 sales and earnings conference call
with institutional investors and analysts at 8:00 a.m. EST on Wednesday,
Feb. 5. During the call, company executives will provide an overview of
Merck’s performance for the quarter.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - January 6, 2014 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Merck Announces Launch of a New Business Focused on Comprehensive, Evidence-Based Weight Management Interventions in the U.S.
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the launch of a new business focused on providing
comprehensive, evidence-based weight management interventions for
employers, hospitals, medical groups, health plans and patients.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 908-423-5042orRobe...
Source: Merck.com - Corporate News - December 20, 2013 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
MSD Animal Health Receives Positive Opinion from European Medicines Agency for BRAVECTO™ (fluralaner)
Dateline City:
SUMMIT, N.J.
New Chewable Tablet Treatment for Fleas and Ticks in Dogs – Effective For 12 Weeks (8 weeks for Rhipicephalus sanguineus ticks)
SUMMIT, N.J.--(BUSINESS WIRE)--MSD Animal Health (known as Merck Animal Health in the United States and
Canada) today announced that the Committee for Medicinal Products for
Veterinary Use (CVMP) of the European Medicines Agency has adopted a
positive opinion, recommending the granting of a marketing authorization
...
Source: Merck.com - Corporate News - December 17, 2013 Category: Pharmaceuticals Tags: Corporate News Animal Health Latest News Source Type: news
Merck Advances Development Program for Investigational Alzheimer’s Disease Therapy, MK-8931
Dateline City:
WHITEHOUSE STATION, N.J.
Data Monitoring Committee recommends continuation of Phase II/III EPOCH study in mild to moderate disease patients
Merck also plans to initiate dosing in Phase III study of prodromal disease patients
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today provided an update on the development program for MK-8931, a novel
investigational oral β-amyloid precurs...
Source: Merck.com - Corporate News - December 10, 2013 Category: Pharmaceuticals Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck Announces Increased Quarterly Dividend
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Board of Directors has increased the company’s
quarterly dividend to $0.44 per outstanding share of the company’s
common stock, up $0.01 from $0.43 per outstanding share paid last
quarter. Payment will be made on January 8, 2014, to stockholders of
record at the close of business on December 16, 2013.
Language:
...
Source: Merck.com - Corporate News - November 26, 2013 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
Mondo Guerra and the Merck HIV Educational Campaign I Design Invite the Community to Pledge Action in Honor of World AIDS Day
Dateline City:
WHITEHOUSE STATION, N.J.,
Every Pledge on ProjectIDesign.com Will Reveal a Piece of a New, Community-Created Design
To commemorate World AIDS Day 2013, Merck (NYSE: MRK), known as MSD outside the United States and Canada, is encouraging people impacted by HIV to take action with the educational HIV campaign, I Design. Starting today, visitors to www.ProjectIDesign.com can mark the day by making a pledge to learn more about HIV, educate someone else about the condition, or help themselves or a lo...
Source: Merck.com - Corporate News - November 25, 2013 Category: Pharmaceuticals Tags: I Design Merck. MSD MRK World AIDS Day Corporate News Latest News Source Type: news
Merck for Mothers Working to End the Tragedy of Women in America Dying in Childbirth and Pregnancy
Dateline City:
WHITEHOUSE STATION, N.J.
Initial commitment of $6 million dedicated to addressing growing U.S. problem
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Merck for Mothers has launched programs aimed at decreasing the number of women across the United States who die from or suffer severe complications related to pregnancy and childbirth.The maternal mortality rate in this country has nearly doubled since 1990, despite significant progress in reducing rates ...
Source: Merck.com - Corporate News - November 19, 2013 Category: Pharmaceuticals Tags: maternal mortality Merck Merck for Mothers MRK MSD Corporate News Latest News Source Type: news
Merck Announces Third-Quarter 2013 Financial Results
Dateline City:
WHITEHOUSE STATION, N.J.
2013 Third-Quarter Non-GAAP EPS of $0.92, Excluding Certain Items; GAAP EPS of $0.38
Worldwide Sales were $11.0 Billion, a Decrease of 4 Percent Reflecting the Unfavorable Impact of Patent Expiries and a 2 Percent Negative Impact from Foreign Exchange
Strong Growth in Vaccines and Immunology as well as ISENTRESS
‘Breakthrough Therapy’ Designation Granted for MK-5172/MK-8742, in Development for ...
Source: Merck.com - Corporate News - October 28, 2013 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News Source Type: news
The Merck Manual Go-To Home Guide for Symptoms Helps Patients Assess When to Worry and When to Wait, Determine Next Steps
Dateline City:
WHITEHOUSE STATION, N.J.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the availability of a newly published book, The Merck Manual Go-To Home Guide for Symptoms, which offers essential information on when to seek medical attention and when it may suffice for consumers to address their ailments at home.
Language:
English
Ticker Slug:
Ticker: MRK Exchange: NYSE
Multimedia...
Source: Merck.com - Corporate News - October 23, 2013 Category: Pharmaceuticals Tags: Merck Merck Manual MRK MSD Robert S. Porter Corporate News Latest News Source Type: news
Results from a New Poll: Many Adults Aged 60-Plus Plan to Take Steps to Avoid Flu but Not Other Potentially Preventable Diseases Such as Shingles
Dateline City:
WHITEHOUSE STATION, N.J.
Reinforces Need for Healthcare Professionals and Patients to Discuss Shingles
Flu is at the top of the list of diseases older adults plan to ask about, according to results from a new Harris Interactive consumer awareness survey, sponsored by Merck (NYSE: MRK), known as MSD outside the United States and Canada. Most (68 percent) of the more than 600 surveyed adults age 60 and older are at least somewhat likely to ask their healthcare professional (doctors or pharmacists) ...
Source: Merck.com - Corporate News - October 8, 2013 Category: Pharmaceuticals Tags: chickenpox Eddy Bresnitz herpes zoster Merck MRK MSD shingles zostavax Vaccine News Corporate News Latest News Source Type: news
